Smith & Nephew (LON:SN) Earns “Buy” Rating from Berenberg Bank

Share on StockTwits

Smith & Nephew (LON:SN)‘s stock had its “buy” rating reissued by equities researchers at Berenberg Bank in a research note issued on Monday, Digital Look reports. They presently have a GBX 2,250 ($29.40) target price on the stock. Berenberg Bank’s price target would suggest a potential upside of 32.82% from the company’s current price.

Several other brokerages have also recently commented on SN. Deutsche Bank reaffirmed a “hold” rating on shares of Smith & Nephew in a research report on Friday, July 12th. Shore Capital reissued a “sell” rating on shares of Smith & Nephew in a research report on Monday. Finally, UBS Group lifted their price objective on Smith & Nephew from GBX 1,730 ($22.61) to GBX 1,830 ($23.91) and gave the company a “neutral” rating in a research report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. Smith & Nephew presently has an average rating of “Hold” and an average price target of GBX 1,654.38 ($21.62).

Shares of Smith & Nephew stock opened at GBX 1,694 ($22.14) on Monday. The stock has a market cap of $14.53 billion and a PE ratio of 21.25. The business has a fifty day simple moving average of GBX 1,897.03 and a 200-day simple moving average of GBX 1,749.70. The company has a quick ratio of 0.96, a current ratio of 2.00 and a debt-to-equity ratio of 44.00. Smith & Nephew has a 12 month low of GBX 1,242.50 ($16.24) and a 12 month high of GBX 1,998.40 ($26.11).

In other news, insider Virginia Bottomley acquired 201 shares of Smith & Nephew stock in a transaction that occurred on Friday, August 23rd. The stock was purchased at an average price of GBX 1,939 ($25.34) per share, with a total value of £3,897.39 ($5,092.63).

Smith & Nephew Company Profile

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Recommended Story: Why is a lock-up period needed for an IPO?

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Short Interest in Waterstone Financial, Inc.  Increases By 6.1%
Short Interest in Waterstone Financial, Inc. Increases By 6.1%
Viacom, Inc.  Short Interest Up 7.4% in October
Viacom, Inc. Short Interest Up 7.4% in October
Zynerba Pharmaceuticals Inc  Short Interest Down 10.5% in October
Zynerba Pharmaceuticals Inc Short Interest Down 10.5% in October
FAT Brands  Downgraded to “Hold” at ValuEngine
FAT Brands Downgraded to “Hold” at ValuEngine
Crestwood Equity Partners  Stock Rating Lowered by ValuEngine
Crestwood Equity Partners Stock Rating Lowered by ValuEngine
AGM Group  Stock Rating Upgraded by ValuEngine
AGM Group Stock Rating Upgraded by ValuEngine


© 2006-2019 Ticker Report